birinapant
Small moleculeexperimental
Clinical trial activity
12 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT00993239)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Hepatitis B · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- cIAP1/cIAP2INHIBITOR
cIAP1/cIAP2 inhibitor
Specifically target cIAP1 and cIAP2 for degradation, resulting in a switch in TNFR signaling that leads to activation of caspase-8 and induction of apoptosis
Specifically targets cIAP1 and cIAP2
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12- Mol. weight
- 806.96 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039522 ↗
Also known as
- birinapant
- birinapant
- birinapant
- birinapant
- birinapant
- tl32711
- tl32711
- tl32711
- tl-32711
- tl-32711
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03803774 | Phase 1 | Jan 7, 2019 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT02587962 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2017 | Merck, TetraLogic Pharmaceuticals |
| NCT02756130 | Phase 2 | Jan 1, 2017 | TetraLogic Pharmaceuticals, University of California, Los Angeles |
| NCT02288208 | Phase 1 | Nov 1, 2014 | TetraLogic Pharmaceuticals |
| NCT02147873 | Phase 2 | Jun 1, 2014 | TetraLogic Pharmaceuticals |
| NCT01940172 | Phase 1 | Nov 1, 2013 | TetraLogic Pharmaceuticals |
| NCT01828346 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2013 | TetraLogic Pharmaceuticals, University of Texas at Houston |
| NCT01681368 | Phase 2 | Aug 15, 2012 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01573780 | Phase 1 | Apr 1, 2012 | National Cancer Institute (NCI), State University of New York, Buffalo, TetraLogic Pharmaceuticals |
| NCT01486784 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2011 | University of Pennsylvania |
| NCT01188499 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Mary Crowley Cancer Center, South Texas Accelerated Research Therapeutics, State University of New York, Buffalo, Temple University, TetraLogic Pharmaceuticals, University of Pennsylvania, Wayne State University |
| NCT00993239 | Phase 1 | Nov 1, 2009 | State University of New York, Buffalo, Temple University, TetraLogic Pharmaceuticals, University of Pennsylvania |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TetraLogic Pharmaceuticals | For profit | 9 | 7 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 2012 |
| State University of New York, Buffalo | Academic/Hospital | 3 | 1 | 2 | 2009 |
| University of Pennsylvania | Academic/Hospital | 3 | 1 | 2 | 2009 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2012 |
| Temple University | Academic/Hospital | 2 | 0 | 2 | 2009 |
| Mary Crowley Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| South Texas Accelerated Research Therapeutics | For profit | 1 | 0 | 1 | 2010 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2010 |
12 organizations
Page 1 / 1